Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05619887
Other study ID # Muscle_reflex_hypoxia
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2023
Est. completion date June 2024

Study information

Verified date November 2022
Source University of British Columbia
Contact Travis D Gibbons, PhD
Phone 778.583.6976
Email travis.gibbons@ubc.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this interventional study is to compare muscle reflex function under settings of normoxia (normal oxygen level), acute hypoxia (brief oxygen-lack) and chronic hypoxia (long-duration exposure to oxygen-lack). The main question is: Does the muscle reflex adapt to chronic hypoxia? Young, healthy participants will complete light-to-high intensity cycling exercise with and without suppression of the muscle reflex. Suppression of the muscle reflex will be via spinal administration of the opioid Fentanyl. In the control condition, saline will be administered into the spinal space. Participants will complete control (saline) and experimental (Fentanyl) exercise conditions at sea-level (Kelowna, BC, Canada) breathing room air and whilst breathing a lower fraction of oxygen (acute hypoxia). Thereafter, participants will complete the exercise test after living at high altitude (White Mountain, CA, USA) for 2 weeks whilst breathing room air (chronic hypoxia) and breathing a higher fraction of oxygen (restored normoxia).


Description:

Purpose: To determine whether muscle reflex control of cardiorespiratory function is sensitized by chronic exposure to low oxygen environments. To do this, fentanyl will be administered into the lumbar spine to suppress nerve activity coming from the muscle during upright cycling exercise. Hypothesis: Cardiorespiratory responses (ventilation, blood pressure and heart rate) to cycling exercise will be suppressed when muscle reflex activity is partially blocked with fentanyl administration. This suppression will be augmented in a dose-dependent manner with the duration of hypoxic exposure. Design: This is a repeated measures cross-over design with participants completing control (saline) and experimental (fentanyl) conditions both low and high altitude; a total of six visits is required. Sea level testing sessions will involve a cycling exercise bout while breathing room air and a second exercise bout breathing a hypoxic gas mixture meant to simulate the altitude at White Mountain. High altitude testing sessions will involve the same cycling exercise bout while breathing room air and another exercise bout while breathing a hyperoxic gas mixture meant to simulate the altitude in Kelowna. Cardiorespiratory (ventilation, blood pressure and heart rate) will be measured throughout with (fentanyl) and without (saline) muscle reflex suppression. A 7-km time trial test will be performed during each visit to determine how the muscle reflex influences exercise performance. Experimental procedures: Participants will visit the lab on six occasions; 3 in both Kelowna and White Mountain. Participants will be requested to practice regular exercise and dietary habits that can be easily replicated in the 24 hours prior to every laboratory visit. Exercise and dietary patterns will be documented during the first visit and thereafter the participants will be reminded of these practices and instructed to match them as closely as possible in the 24 hours leading up to all subsequent visits. Participants will only be instructed to avoid heavy exercise in the 12 hours prior to testing sessions. On the first visit (Kelowna), participants will be introduced into the lab, where we will give oral and written instruction detailing the procedures and associated risks related to participating. Details of the experimental visits are outlined below: Sea level: - Familiarization and fitness test (1 h) General introduction to the lab, testing equipment and measurements devices. Maximal aerobic power test on an upright cycle ergometer. - Main experimental visit #1, saline or fentanyl (2 h) Invasive cannulas will be inserted and drugs administered by an anesthetist. Complete four steady-state exercise bouts (3 min each) while breathing room air. After a 2 min wash-in, complete four steady-state exercise bouts (3 min each) while breathing hypoxic gas (FiO2 = 0.15). Complete a 7 km time trial test. - Main Experimental visit #2, Intrathecal (spinal) saline or fentanyl (2 h) Complete identical procedures as experimental visit #1, but the opposite condition. High altitude: - High altitude fitness test #1 (30 min) Maximal aerobic power test on upright cycle ergometer. - Main experimental visit #3, saline or fentanyl (2 h) Invasive cannulas will be inserted and drugs administered by an anesthetist. Complete four steady-state exercise bouts (3 min each) while breathing room air. After a 2 min wash-in, complete four steady-state exercise bouts (3 min each) while breathing hyperoxic gas (FiO2 = 0.30). Complete a 7 km time trial test. - Main experimental visit #4, saline or fentanyl (2 h) Complete identical procedures as experimental visit #3, but the opposite condition.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 14
Est. completion date June 2024
Est. primary completion date December 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 40 Years
Eligibility Inclusion Criteria: - aged 19 - 40 years old - not taking medications (exception oral contraception) - no history of cardiovascular, respiratory or neurological disease - members of the high altitude expedition to White Mountain in 2023 Exclusion Criteria: - post-menopausal or pregnant - obese - current smokers - taking prescription medications that may affect responses to exercise All potential participants will be screened by a physician to identify co-morbidities

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fentanyl
Fentanyl, when administered into the intrathecal (spinal) space suppresses feedback from the muscles below the site of action, i.e., the legs. It does not affect resting cardiorespiratory responses. We are using this to test what role the muscle reflex plays during exercise.
Other:
Saline
An equal volume (as above) of saline will be administered into the intrathecal (spinal) space. This has no effect of cardiorespiratory responses at rest or during exercise; it is to control for the invasiveness of the procedure required to suppress muscle feedback in the experimental condition.

Locations

Country Name City State
Canada University of British Columbia - Okanagan Campus Kelowna British Columbia

Sponsors (1)

Lead Sponsor Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

References & Publications (2)

Amann M, Proctor LT, Sebranek JJ, Pegelow DF, Dempsey JA. Opioid-mediated muscle afferents inhibit central motor drive and limit peripheral muscle fatigue development in humans. J Physiol. 2009 Jan 15;587(1):271-83. doi: 10.1113/jphysiol.2008.163303. Epub — View Citation

Wan HY, Weavil JC, Thurston TS, Georgescu VP, Bledsoe AD, Jessop JE, Buys MJ, Richardson RS, Amann M. The muscle reflex and chemoreflex interaction: ventilatory implications for the exercising human. J Appl Physiol (1985). 2020 Oct 1;129(4):691-700. doi: — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Exercise performance Time, in seconds, to complete 7 kilometers of cycling, i.e. a time-trial The duration, i.e., however long it takes to complete the exercise; this is typically 7-14 minutes
Primary Ventilation Ventilation, in liters per minute. Data collected during steady-state breathing in the last minute of exercise
Secondary Mean arterial blood pressure (entire pressure wave) Blood pressure, in millimeters of mercury Data collected during steady-state breathing in the last minute of exercise
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04688905 - Diagnosing Heart Failure With Preserved Ejection Fraction in Patients With Unexplained Dyspnea (Diagnose-HFpEF)
Completed NCT03679312 - The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD Phase 1/Phase 2
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Active, not recruiting NCT03604822 - Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS N/A
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Completed NCT02638649 - Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
Completed NCT02538770 - Rapid Viral Diagnostics in Adults to Reduce Antimicrobial Consumption and Duration of Hospitalization N/A
Completed NCT02248831 - Evaluation of Cardiopulmonary Diseases by Ultrasound N/A
Terminated NCT02269761 - Chest Ultrasound of ER Patients With Cough or SOB
Recruiting NCT01655199 - Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With Chronic Obstructive Pulmonary Disease N/A
Active, not recruiting NCT01440764 - Aerosol Inhalation Treatment for Dyspnea Phase 1/Phase 2
Completed NCT01577407 - Non Opioid Treatment for Experimental Dyspnea Phase 3
Completed NCT01193998 - Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department N/A
Recruiting NCT04327882 - Point-of-care Ultrasound Interest in Dyspneic Emergency Department Patients: an Observational Bicentric Study
Completed NCT05029986 - Preventing Dyspnea During Speech in Older Speakers N/A
Not yet recruiting NCT04181359 - The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease. Phase 1/Phase 2
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Completed NCT04305639 - The Reliability and Validity of Turkish Version of ''The Dyspnea-ALS-Scale (DALS-15)"
Completed NCT04375917 - Is Reduced Hypoxia Through a Robot Intervention, Associated With Sensory and Emotional Descriptions of Dyspnea, Anxiety, Depression, Symptom Burden and Anxiolytics N/A
Completed NCT04370990 - Automated Oxygen Administration -Rethinking Interventions Alleviating Dyspnea in Patients With COPD N/A